AstraZeneca, through its Alexion subsidiary, has entered an agreement to acquire LogicBio Therapeutics, Inc. for $68 million, enhancing AstraZeneca’s efforts in genomics and rare diseases.   Lexington, MA-based LogicBio, is a clinical-stage genomic medicine company with unique technology, experienced rare disease R&D team, and expertise in preclinical development, which will support Alexion’s growth in genomic medicines. Alexion plans to retain LogicBio employees at their current loc...